Balloon Dilation of the Eustachian Tube
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Defines medical necessity criteria, coding, and coverage stance for balloon dilation of the eustachian tube (BDET) for BCBS North Carolina members, primarily affecting adult ENT providers performing BDET.
Policy statement revised to explicitly state BCBSNC will provide coverage when medical criteria and guidelines shown are met.
When Covered section updated with specific medically necessary criteria for BDET (e.g., symptom duration, diagnostic assessment, failure of medical management, contraindications).
Description updated to reflect changes in indications and duration requirement (ETD symptoms must be present for three months instead of twelve).
Removed Samter's Triad from the list of contraindications and removed laryngopharyngeal reflux as a potential co-occurring condition in a criterion.
Added/update of applicable FDA-cleared devices and regulatory status listing multiple de novo 510(k) devices through 2023.
Coverage Criteria for Balloon Dilation of the Eustachian Tube (BDET)
Initial BDET Coverage Criteria
Covered when ALL of the following are met
Symptoms of obstructive ETD
- Symptom components: Aural fullness; aural pressure; symptoms present for three months or longer; symptoms are continuous or recurrent in response to barochallenges (e.g., flying, scuba diving, or other pressure changes) provided they significantly affect quality of life or functional health status>=3 months
Diagnostic findings (any of the following)
- Abnormal tympanogram (Type B or C)
- Abnormal TM: Abnormal tympanic membrane (retracted membrane, effusion, perforation, or any other abnormality identified on exam)
- Failure of medical management: Failure to respond to appropriate medical management of potential co-occurring conditions (e.g., allergic rhinitis or rhinosinusitis), including 4 to 6 weeks of a nasal steroid spray unless contraindicated4-6 weeks nasal steroid trial when indicated
- Other causes ruled out: Other causes of aural fullness (temporomandibular joint disorders, extrinsic obstruction of the eustachian tube, superior semicircular canal dehiscence, endolymphatic hydrops) have been ruled out
- Temporarily reversible ETD: ETD has been shown to be temporarily reversible
Trans‑tympanic balloon dilation of the eustachian tube and repeat BDET procedures on the same ear are designated as investigational. Claims for these techniques will be reviewed under that investigational stance and are not covered as standard treatment options.
Balloon dilation of the eustachian tube (BDET) is considered investigational and therefore not covered when the policy’s specified medical criteria are not met. In addition, repeat BDET on the same ear and trans‑tympanic BDET are specifically identified as investigational and not covered for any indication.
Coding
Provider Actions and Documentation Requirements
Prior authorization and applicable CPT codes
Prior authorization may be required for balloon dilation of the eustachian tube. When submitting authorization or claims, include the applicable procedure codes and documentation demonstrating that all coverage criteria are met.
Conservative therapy requirement (document treatment failure)
Document that the patient failed to respond to appropriate medical management before BDET. This includes, when indicated, a trial of nasal steroid spray for 4–6 weeks unless contraindicated.
- Record specifics of medical management tried (e.g., nasal steroid type, dose, duration — 4–6 weeks when indicated)
- Document persistence of symptoms despite therapy
Medical record submission and documentation sufficiency
BCBSNC may request medical records to determine medical necessity; letters of support alone are insufficient unless they contain all specific information needed for the determination.
- Provide comprehensive diagnostic assessment records: patient questionnaires, history and physical, tympanometry (if TM intact), nasal endoscopy, and audiometry
- Include documentation demonstrating symptom duration, prior medical management, and findings supporting ETD
Denial triggers for BDET claims
Claims may be denied when the documented clinical criteria are not met, for repeat BDET on the same ear, or for trans-tympanic BDET, as these are considered investigational when criteria or restrictions apply.
- Denial risk if patient does not meet all coverage criteria (including symptom duration, diagnostic findings, and no prior BDET in the same ear)
- Repeat BDET on the same ear is investigational and may be denied
- Trans-tympanic BDET is investigational for all indications and may be denied
Background
The eustachian tube helps ventilate the middle ear and maintain pressure equilibrium between the middle ear and nasopharynx. Dysfunction of the eustachian tube (ETD) can cause symptoms such as aural fullness, pressure dysregulation, hearing changes, and recurrent middle ear disease. Balloon dilation of the eustachian tube (BDET) is an endoscopic procedure intended to improve tubal patency; however, when BDET is performed trans‑tympanically or when repeat procedures are performed in the same ear, these approaches are considered investigational and are not covered under this policy.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.